Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2019 Filed Feb 26, 2019 21:33 UTC |
Eddy Jodi EuerleSVP and CIO
|
Exercise / conversionDeferred Stock Units · Derivative | 1,738 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003724 · doc4.xml · derivative · entry 7 Eddy Jodi Euerle · CIK 0001734900 · SVP and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,476 Underlying: Common Stock · 1,738 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:33 UTC |
Eddy Jodi EuerleSVP and CIO
|
Tax withholdingCommon Stock | 497 | $40.52 | $20,138.44 |
DisclosureSEC source: 0001225208-19-003724 · doc4.xml · nonDerivative · entry 2 Eddy Jodi Euerle · CIK 0001734900 · SVP and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,437 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:33 UTC |
Eddy Jodi EuerleSVP and CIO
|
Exercise / conversionCommon Stock | 1,738 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003724 · doc4.xml · nonDerivative · entry 1 Eddy Jodi Euerle · CIK 0001734900 · SVP and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:33 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionDeferred Stock Units · Derivative | 2,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003723 · doc4.xml · derivative · entry 7 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,636 Underlying: Common Stock · 2,317 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:33 UTC |
Carruthers WendySVP, Human Resources
|
Tax withholdingCommon Stock | 1,030 | $40.52 | $41,735.60 |
DisclosureSEC source: 0001225208-19-003723 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,693 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:33 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionCommon Stock | 2,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003723 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:33 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
Exercise / conversionDeferred Stock Units · Derivative | 1,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003721 · doc4.xml · derivative · entry 8 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,028 Underlying: Common Stock · 1,014 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:33 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
Tax withholdingCommon Stock | 478 | $40.52 | $19,368.56 |
DisclosureSEC source: 0001225208-19-003721 · doc4.xml · nonDerivative · entry 2 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,819 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:33 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
Exercise / conversionCommon Stock | 1,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003721 · doc4.xml · nonDerivative · entry 1 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:33 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionDeferred Stock Units · Derivative | 5,794 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003720 · doc4.xml · derivative · entry 7 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,588 Underlying: Common Stock · 5,794 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:33 UTC |
Brennan Daniel J.EVP and CFO
|
Tax withholdingCommon Stock | 2,576 | $40.52 | $104,379.52 |
DisclosureSEC source: 0001225208-19-003720 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,890 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:33 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionCommon Stock | 5,794 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003720 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:32 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionDeferred Stock Units · Derivative | 3,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003719 · doc4.xml · derivative · entry 7 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,532 Underlying: Common Stock · 3,766 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:32 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Tax withholdingCommon Stock | 1,718 | $40.52 | $69,613.36 |
DisclosureSEC source: 0001225208-19-003719 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,912 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:32 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionCommon Stock | 3,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003719 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:42 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
GrantStock Option (Right to Buy) · Derivative | 22,195 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-19-003573 · doc4.xml · derivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,195 Underlying: Common Stock · 22,195 shares Expires 2029-02-21 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:42 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
GrantDeferred Stock Units · Derivative | 6,854 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003573 · doc4.xml · derivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,854 Underlying: Common Stock · 6,854 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:42 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
GrantStock Option (Right to Buy) · Derivative | 14,124 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-19-003572 · doc4.xml · derivative · entry 2 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,124 Underlying: Common Stock · 14,124 shares Expires 2029-02-21 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:42 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
GrantDeferred Stock Units · Derivative | 4,361 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003572 · doc4.xml · derivative · entry 1 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,361 Underlying: Common Stock · 4,361 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:42 UTC |
Ralls-Morrison DesireeSVP, GC and Corp Secretary
|
GrantStock Option (Right to Buy) · Derivative | 17,150 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-19-003571 · doc4.xml · derivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,150 Underlying: Common Stock · 17,150 shares Expires 2029-02-21 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:42 UTC |
Ralls-Morrison DesireeSVP, GC and Corp Secretary
|
GrantDeferred Stock Units · Derivative | 5,296 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003571 · doc4.xml · derivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,296 Underlying: Common Stock · 5,296 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:42 UTC |
Pierce David AEVP,Pres MedSurg
|
GrantStock Option (Right to Buy) · Derivative | 32,284 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-19-003570 · doc4.xml · derivative · entry 2 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,284 Underlying: Common Stock · 32,284 shares Expires 2029-02-21 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:42 UTC |
Pierce David AEVP,Pres MedSurg
|
GrantDeferred Stock Units · Derivative | 9,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003570 · doc4.xml · derivative · entry 1 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,970 Underlying: Common Stock · 9,970 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:41 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
GrantStock Option (Right to Buy) · Derivative | 22,195 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-19-003569 · doc4.xml · derivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,195 Underlying: Common Stock · 22,195 shares Expires 2029-02-21 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:41 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
GrantDeferred Stock Units · Derivative | 6,854 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003569 · doc4.xml · derivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,854 Underlying: Common Stock · 6,854 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:40 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
GrantStock Option (Right to Buy) · Derivative | 36,319 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-19-003568 · doc4.xml · derivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,319 Underlying: Common Stock · 36,319 shares Expires 2029-02-21 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:40 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
GrantDeferred Stock Units · Derivative | 11,216 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003568 · doc4.xml · derivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,216 Underlying: Common Stock · 11,216 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:39 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
GrantStock Option (Right to Buy) · Derivative | 13,115 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-19-003567 · doc4.xml · derivative · entry 2 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,115 Underlying: Common Stock · 13,115 shares Expires 2029-02-21 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:39 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
GrantDeferred Stock Units · Derivative | 4,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003567 · doc4.xml · derivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,050 Underlying: Common Stock · 4,050 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:37 UTC |
Mackey Edward FEVP, Operations
|
GrantStock Option (Right to Buy) · Derivative | 35,310 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-19-003565 · doc4.xml · derivative · entry 2 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,310 Underlying: Common Stock · 35,310 shares Expires 2029-02-21 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:37 UTC |
Mackey Edward FEVP, Operations
|
GrantDeferred Stock Units · Derivative | 10,904 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003565 · doc4.xml · derivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,904 Underlying: Common Stock · 10,904 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:39 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 217,917 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-19-003566 · doc4.xml · derivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,917 Underlying: Common Stock · 217,917 shares Expires 2029-02-21 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:39 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
GrantDeferred Stock Units · Derivative | 67,298 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003566 · doc4.xml · derivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,298 Underlying: Common Stock · 67,298 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:37 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
GrantStock Option (Right to Buy) · Derivative | 50,443 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-19-003564 · doc4.xml · derivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,443 Underlying: Common Stock · 50,443 shares Expires 2029-02-21 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:37 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
GrantDeferred Stock Units · Derivative | 15,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003564 · doc4.xml · derivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,578 Underlying: Common Stock · 15,578 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:35 UTC |
Eddy Jodi EuerleSVP and CIO
|
GrantStock Option (Right to Buy) · Derivative | 12,106 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-19-003563 · doc4.xml · derivative · entry 2 Eddy Jodi Euerle · CIK 0001734900 · SVP and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,106 Underlying: Common Stock · 12,106 shares Expires 2029-02-21 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:35 UTC |
Eddy Jodi EuerleSVP and CIO
|
GrantDeferred Stock Units · Derivative | 3,738 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003563 · doc4.xml · derivative · entry 1 Eddy Jodi Euerle · CIK 0001734900 · SVP and CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,738 Underlying: Common Stock · 3,738 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:35 UTC |
Carruthers WendySVP, Human Resources
|
GrantStock Option (Right to Buy) · Derivative | 20,177 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-19-003562 · doc4.xml · derivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,177 Underlying: Common Stock · 20,177 shares Expires 2029-02-21 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:35 UTC |
Carruthers WendySVP, Human Resources
|
GrantDeferred Stock Units · Derivative | 6,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003562 · doc4.xml · derivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,231 Underlying: Common Stock · 6,231 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:35 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,225 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-19-003561 · doc4.xml · derivative · entry 6 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,874 Underlying: Common Stock · 15,225 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:35 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
GrantStock Option (Right to Buy) · Derivative | 22,195 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-19-003561 · doc4.xml · derivative · entry 5 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,195 Underlying: Common Stock · 22,195 shares Expires 2029-02-21 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:35 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
GrantDeferred Stock Units · Derivative | 6,854 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003561 · doc4.xml · derivative · entry 4 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,854 Underlying: Common Stock · 6,854 shares Expires 2023-02-21 F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:35 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
SaleCommon Stock | 15,225 | $39.95 | $608,238.75 |
DisclosureSEC source: 0001225208-19-003561 · doc4.xml · nonDerivative · entry 2 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,283 F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:35 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
Exercise / conversionCommon Stock | 15,225 | $7.16 | $109,011.00 |
DisclosureSEC source: 0001225208-19-003561 · doc4.xml · nonDerivative · entry 1 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,508 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:32 UTC |
Brennan Daniel J.EVP and CFO
|
GrantStock Option (Right to Buy) · Derivative | 47,417 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-19-003560 · doc4.xml · derivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,417 Underlying: Common Stock · 47,417 shares Expires 2029-02-21 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:32 UTC |
Brennan Daniel J.EVP and CFO
|
GrantDeferred Stock Units · Derivative | 14,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003560 · doc4.xml · derivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,643 Underlying: Common Stock · 14,643 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:31 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
GrantStock Option (Right to Buy) · Derivative | 38,337 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-19-003559 · doc4.xml · derivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,337 Underlying: Common Stock · 38,337 shares Expires 2029-02-21 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:31 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
GrantDeferred Stock Units · Derivative | 11,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003559 · doc4.xml · derivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,839 Underlying: Common Stock · 11,839 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 23:11 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
GrantPerformance Share Units · Derivative | 19,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003433 · doc4.xml · derivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,038 Underlying: Common Stock · 19,038 shares Expires 2020-12-31 F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · shares: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. F4 · derivative.exercise_date: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. F4 · derivative.expiration_date: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. F4 · balance_after: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 23:11 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Tax withholdingCommon Stock | 16,758 | $40.11 | $672,163.38 |
DisclosureSEC source: 0001225208-19-003433 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,864 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.